KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Shares Outstanding (2016 - 2025)

Alnylam Pharmaceuticals' Shares Outstanding history spans 17 years, with the latest figure at $132.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 2.38% year-over-year to $132.4 million; the TTM value through Dec 2025 reached $132.4 million, up 2.38%, while the annual FY2025 figure was $132.4 million, 2.38% up from the prior year.
  • Shares Outstanding reached $132.4 million in Q4 2025 per ALNY's latest filing, roughly flat from $131.8 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $132.4 million in Q4 2025 to a low of $117.3 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $125.1 million, with a median of $125.2 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: increased 3.67% in 2021, then grew 1.51% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $120.2 million in 2021, then increased by 3.11% to $123.9 million in 2022, then increased by 1.51% to $125.8 million in 2023, then increased by 2.78% to $129.3 million in 2024, then rose by 2.38% to $132.4 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Shares Outstanding are $132.4 million (Q4 2025), $131.8 million (Q3 2025), and $131.0 million (Q2 2025).